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As a result of the continuous decline in the rate of infectious 
diseases, cancer has become a major cause of morbidity and mortality, 
thus becoming an important target of scientifi c research. One of the 
most remarkable features of experimental cancer research has been 
the way it opened up fi elds of research that are interesting in their own 
right. At the end of the nineteenth century, scientists studied certain 
infectious tumors like warts in children and infectious leukemia 
of chickens, which led to the discovery of some of the fi rst viruses 
known to infect animals. In the early twentieth century, microscopic 
examination of cancer cells revealed that they oft en contain abnormal 
chromosomes. It was believed that cancer cells pass on its abnormality 
in behavior to its descendants. Th erefore, this was important evidence 
that inherited characteristics were carried by chromosomes. 
Early attempts to transplant tumors from one animal to another 
were largely unsuccessful; however, this failure led to the discovery 
of cellular immunity and the diff erent blood groups which, in turn, 
made blood transfusion possible. Trials to breed lines of mice with 
raised susceptibility to various kinds of cancer led to the discovery of 
histocompatibility antigens [1] paving the way to organ transplants. 
Th is fl ow of information from cancer research into basic biology 
continued through the twentieth century. While the fi eld of molecular 
biology of cancer strived to bare the etiology of cancer or to produce a 
cure, it had enormously increased the understanding of the molecular 
biology of mammalian cells. In fact, many of the techniques used in 
what is called genetic engineering were originally developed from the 
study of cancer cells [2].
Th e period of the 1970s carried a signifi cant turning point in the 
understanding of the pathogenesis of cancer. It became clear that 
the behavior of cells was governed by control of gene expression and 
regulation. Researchers concluded that cancer represented a defect 
in the functioning of the genes concerned with the regulation of cell 
growth and territoriality. Resistance, however, was observed to the 
idea that the study of gene regulation and the control of cell division 
in creatures like bacteria and yeast could illuminate the behavior of 
cancer cells [3].
Th e Industrial Revolution era had resulted in large numbers 
of people being exposed to toxic substances that were not part of 
the normal human environment, and by the end of the nineteenth 
century, factory workers who were continually exposed to harsh 
chemicals developed cancer in the exposed areas of their skin. It was 
natural to test the eff ects of these substances in animals. Most animals, 
however, have much thicker skins than humans do, and the results 
were negative until the experimenters used rabbits and mice. By the 
time of World War I, the list of procedures known to produce cancer 
in animals consisted of infection with certain viruses, x - irradiation, 
and prolonged exposure of the skin to harsh chemicals.
Th e emergence of the fi eld genetics quickly led to the suggestion 
that cancer was a result of mutations arising during cell division 
[2]. Th is view was strengthened when x - rays were shown to cause 
mutations in the fruit fl y Drosophila, [4]. On the other hand; it was 
not clear how chemicals and viruses cause cancer. In the 1920s, the 
disciplines of biochemistry and genetics had little in common, and 
neither had much contact with cancer research. A concerted eff ort 
was made to determine the structure of the compounds in coal tar 
that cause cancer in the hope that an understanding of their chemistry 
would lead to an understanding of a mechanism for the disease [5]. 
Th irty years later, it was the discovery of the structure of DNA that 
started a scientifi c revolution. Th is time, however; knowledge of 
structure carried no obvious message. Coal tar contained a huge 
array of organic compounds, some of which were carcinogenic and 
some not [5]. Many of the compounds were quite toxic when fed to 
animals, which was a little surprising because most of them were not 
soluble in water and were very stable. It appeared to be a general rule 
that the carcinogenic compounds were fl at (atoms were arranged in 
a two dimensional array, like a plate) whereas the non-carcinogenic 
compounds were buckled (atoms did not all lie in the same plane). It 
is known now that the compounds have to be fl at to slip in between 
adjacent base pairs in DNA and cause error mutations during DNA 
replication, but no one could possibly have deduced that in the 1930s. 
Th e infusion from genetics and later from microbiology helped a great 
deal in understanding the structure of carcinogens via the discovery 
of DNA (which came from the study of microorganisms), and then in 
the study of chemical mutagenesis (also in microorganisms). 
Researchers struggled to fi nd a strong correlation between the 
potency of chemical as a mutagen and its potency as a carcinogen. In 
the mid -1930s, Eric Boyland, et al. [6], an English chemist, suggested 
that the more toxic compounds found in coal tar might be detoxifi ed 
in the body by being oxidized by liver enzymes, and the active 
ingredient in the production of cancer might not be the substance 
given to the host but rather one of the intermediates formed from 
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the starting chemical during its detoxifi cation in the liver. Whether 
a compound was carcinogenic or not, it could depend on whether 
it was converted in the body into a mutagenic intermediate and 
whether that intermediate product reached a tissue that could give 
rise to cancer cells. Th is idea turned out to be correct. It explained 
the reasons why a compound could be carcinogenic for one species 
but not for another. For example, early in the 1960s, a chemical called 
2 - acetyl - aminofl uorine (2AAF) was shown to be carcinogenic in 
mice but not in guinea pigs. Th e explanation was that guinea pigs did 
not possess the enzyme converting 2AAF into the oxidation product 
N - hydroxy - 2AAF, which was the actual proximate carcinogen 
and was equally carcinogenic for mice and guinea pigs [7]. Inherited 
diff erences like this might explain why some species were more 
susceptible to certain forms of cancer than to others. 
As soon as genes were shown to be made of DNA, it was natural 
to suppose that the carcinogenic coal tar derivatives produced cancer 
because they were damaging DNA, especially since they could be 
shown to interact with DNA. Curiously enough, this idea was initially 
ridiculed by the cancer research community. Even as late as 1960s, 
ten years aft er the structure of DNA was worked out, the belief was 
that cancer was the result of damage to proteins [7]. However, as the 
list of experimental carcinogens became longer and nearly all were 
shown to cause sequence changes in the DNA of bacteria and animal 
cells, the arguments gradually died down. Tests for mutagens were 
developed leading the research community to believe that these tests 
would allow scientists to identify and eradicate the main causes of 
cancer. On the contrary, the causes of most human cancers remained 
not fully understood.
A noticeable feature of cancer is that it takes a long time to develop 
and for its signs to become visible. When experimental animals or 
humans are continuously exposed to some carcinogenic stimulus, a 
large fraction of their lifetime may have to pass before they start to 
develop cancer. One very early suggestion, dating from the 1940s, 
was that the well-regulated behavior of normal cells was a Mendelian 
dominant character [7]. In other words, one could imagine that each 
cell has one particular gene that controls its behavior, and that both 
copies of this gene have to he mutated before the cell can grow and 
form a cancer. However, here too, the idea that cancer was a matter 
of mutation was not accepted by the cancer research community who 
did not wish to see their subject being turned into a branch of genetics. 
In fact, the hypothesis that some cancers were caused by recessive 
mutations languished unnoticed for about thirty years before being 
resuscitated as a description of certain familial cancers.
Apart from the circulating hormones and the specialized systems 
of communication between nerve cells and between nerves and 
muscles, virtually nothing was known about cell signaling until the 
late 1970s. Natural and experimental cancers appeared to be the end 
result of a sequence of steps. It was diffi  cult to see how these steps 
could ever be determined at the molecular level. Bacteria provided 
a potential answer to this matter. During that period of time, it was 
found that bacteria were able to take up DNA from their surroundings 
and join it up to their own DNA. 
Th e term oncogene was later used and three genes src, ras, and 
myc led the way in the understanding of the pathogenesis of cancer. 
Researchers were successful in making cultured mammalian cells 
to behave similarly in a laboratory environment. Raw DNA, taken 
from cells transformed by Rous Sarcoma Virus (RSV) [8] and 
transferred to normal cells, transformed a few of the recipients into 
cancer cells. Initially, this example of DNA-mediated transformation 
of mammalian cells was viewed as a rather unexciting technical 
development, because it was already clear that the crucial piece of 
DNA had to be the part containing the RSV sequences (in particular 
the gene called src) [8]. At the end of the 1970s, certain human tumors 
were discovered to contain sequences that behaved just like src because 
the cells’ DNA would transform cultured mouse cells. Unfortunately, 
there did not seem to be any obvious way of determining which of the 
100,000 or so protein -coding and - noncoding genes in a human cell 
were responsible.
In 1982, several groups in the United States simultaneously 
reported that one transforming sequence present in the cells of a 
human bladder cancer was the human version of ras, and that the 
cancer cell’s ras was transforming the recipient cells because it had 
undergone one base change of a GC base pair to a TA base pair that 
changed the twelft h amino acid in the Ras protein from glycine to 
valine [9]. In other words, mammalian cells contained a gene called 
ras; this gene was presumably concerned with some aspect of control, 
because it could lead to cancer if it had undergone a change in 
sequence. Th e rat version of the gene was picked up by a retrovirus 
of rats and underwent a mutation that made it into a dominantly 
acting oncogene, and this converted the virus into a tumor virus. Th e 
mutation in the human equivalent of the gene occurred in one of the 
patient’s bladder cells and this was presumably a crucial step in the 
development of the patient’s bladder cancer.
Th e year 1982 brought another equally startling discovery. Th e 
obvious thought was that the chromosomal rearrangements result 
in abnormal neighbors for the genes next to the junction points and 
that this could be leading to over - expression or under - expression 
of a gene that was important for the regulation of cell behavior. For 
example, Burkitt’s lymphoma aff ected the antibody forming cells 
of lymph glands, and it was common to fi nd that in this cancer the 
end of one of the copies of chromosome 8 in the leukemic cells 
had been exchanged with the end of chromosome 2, 14, or 22 [10]. 
Th e human myc gene was shown to be just next to the breakpoint 
on chromosome 8, and the rearrangement was putting myc under 
the control of regions in chromosome 2 or 14 or 22 that normally 
stimulate the expression of genes involved in antibody synthesis.
Th e third discovery in 1982 concerned the interaction of diff erent 
oncogenes. Mouse cells that could be transformed by the mutant ras 
gene from the human bladder cancer had been cultivated for some 
time and were already slightly abnormal. When normal mouse 
cells were used nothing happened. Th is meant that the CG- to -TA 
mutation in one of the copies of the ras gene was not suffi  cient on 
its own to make a normal cell cancerous. It turned out that normal 
cells could be transformed if they were also given a myc gene that was 
over-expressed through being next to a viral promoter [10]. Here, at 
last was the fi rst worked out example of multi-step carcinogenesis. 
Actually, it was clear that a third step was required to make a fully-
fl edged cancer. Most of the tumors produced mutant ras and over-
expressed myc eventually underwent regression, presumably as the 
result of the kind of programmed cell death that occurred when the 
cells had gone through repeated divisions. Only when the cells were 
“immortalized” by inactivation of a gene for programmed cell death 
would the change in ras and over-expression of myc produce an 
endless proliferating line of cancer cells [10]. Th e generality of the 
ras + myc + immortalization case was strengthened by the discovery 
that certain DNA tumor viruses carrying genes that were analogous 
in function. 
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Th is was an important turning point in the history of cancer 
research. Th e fact that just two particular cell functions were 
involved in the formation of certain natural human cancers and in 
the tumorigenicity of several totally diff erent kinds of tumor viruses 
implied that when cancers arose, it was as the result of defects in a 
limited number of weak points in the control of cell behavior. Since 
1982, the itemizing of these weak points had progressed very rapidly. 
By now, more than 100 such genes have been identifi ed, in which 
a change in sequence or in level of expression can be one of the 
steps in the development of a human cancer [7]. Th at may seem a 
large number, but the genes turn out to belong to a limited number 
of families. Th e normal function of these families of genes is to 
control cell behavior. Th e genes were discovered as the result of their 
involvement in cancer, but obviously the cell does not have them in 
order to expose itself to the risk of becoming cancerous. Th e genes 
are now called proto - oncogenes to distinguish the normal proto - 
oncogene called ras from the mutant ras, which is a cancer producing 
oncogene [7]. Mammalian cells have several copies of ras like genes 
and of the other major classes of proto - oncogenes, each of which is 
presumably under somewhat diff erent regulatory control. Each class 
of cell apparently uses only a few of these. Th e cancers arising in one 
type of cell tend to show changes in one particular member of the ras 
family.
Other equally important genes have been discovered where, 
by contrast, one normal copy of the gene is enough to control cell 
behavior. Th ese were therefore called tumor suppressor genes. Th e 
fi rst example to be identifi ed was a gene involved in the formation 
of a rare tumor of the retina seen in young children. Th e tumor 
developed when both copies of the retinoblastoma gene (rb) had been 
inactivated by mutation [11].Th is could happen in one of two ways 
either the child inherited a mutated gene from one of its parents and 
acquired the second mutation during the growth of the retinal cells, 
or (more rarely) one of the child’s retinal cells acquired mutations 
in each of the genes. Similar suppressor genes had been found to be 
commonly involved in breast and colon cancers, and an inherited 
defect in one of the copies of these genes greatly raised the risk of 
developing breast or colon cancer [11].
Th e ability of complementary sequences (either of DNA or 
RNA) to fi nd each other has been enormously useful. It had allowed 
molecular biologists to isolate particular DNA coding sequences 
from mixtures. For example, if one wanted to isolate the region of 
human DNA that codes for the protein in hemoglobin, one could 
start by isolating the corresponding mRNA from young red cells, 
then chemically binds this mRNA onto some kind of fi lter, if melted 
human single stranded DNA is passed through this fi lter adjusted 
to the right temperature, the fi lter will bind the DNA strands that 
are complementary to the mRNA for hemoglobin and let all the 
other sequences pass through. Th e fi lter would then be treated with 
an enzyme that breaks down RNA, leaving DNA strands that are 
complementary to the mRNA. DNA polymerase can then be used to 
convert the single stranded DNA into double helices, and now the 
separation of globin sequences from all the hundreds of thousands of 
other sequences present in a human cell is achieved. 
To summarize, plants and animals have managed to evolve 
systems of control that generate many diff erent kinds of cells and 
allow large groups of such cells to collaborate together in multi-
cellular arrays. Th is is achieved by a system of communication that 
aff ects every kind of biochemical event occurring within each cell, the 
transcription of genes, the handling and rate of translation of mRNA, 
and fi nally, by protein phosphorylation, the specifi city and level of 
activity of many of the enzymes in the cell. Fortunately for us, the 
systems that regulate our cells’ behavior seem to have excess capacity 
for accommodating defects. For example, a mutation into ras could 
deregulate its stimulatory action on cell division, but this one change 
on its own is not enough to wreck the system. If a cell is to escape its 
network of controls, it has to be damaged in several diff erent ways. 
Th at is why the production of cancer requires the alteration of many 
genes. 
It is only in the last few years that techniques have been available 
to look directly for sequence changes, so researchers have only just 
started to make inventories of the changes found in the various kinds 
of cancer. Th ere is little reason to doubt that nucleic acid probes 
will have applications in the diagnosis of malignancy as well as in 
the assessment of prognosis. Investigators are increasingly viewing 
malignancy as a somatic form of genetic disease. Th e unraveling of 
genetic alterations that form the basis for the clonal development and 
evolution of malignancy is an area of intensive research. Th e inherited 
predisposition for the development of malignancy is another related 
area of investigation with immense clinical potential. 
Not until our understanding of malignancy progresses will 
the diagnostician is able to make use of those tools. Th e transfer 
of technology that has most clearly occurred in the diagnosis of 
infectious disease, where the use of molecular biology is most 
advanced, can be anticipated to occur in the area of cancer biology. 
In fact, this transfer will be expected to be even more rapid as clinical 
laboratories become increasingly attuned to the use of nucleic acid 
probes. Many of the oncogenes have been cloned and mapped to 
specifi c regions of chromosomes; their protein products have been 
characterized and usually are referred to in terms of their molecular 
weight in kilodaltons. 
From this discussion, it can be seen that any of the described 
hybridization analyses could be used to study oncogenes and anti 
- oncogenes in the clinical setting. Antibodies directed against the 
site of mutated oncogene product or demonstrating alterations in 
the quantity of a particular oncogene product could also be used. 
However, the majority of this information is too preliminary to justify 
inclusion in a diagnostic or prognostic evaluation of a particular 
patient’s tumor. Demonstration of changes in oncogenes and anti 
-oncogenes could aid in the classifi cation of tumors, permit earlier 
diagnosis, guide therapy, and allow screening for “cancer prone” 
populations before the development of malignancy. However, in 
most instances the changes that are seen in these oncogenes or anti-
oncogenes are not diagnostic of a particular tumor type and these 
applications remain potential rather than practical and clinical with 
the exception of leukemia and lymphoma. 
Looking to the future, there is a need to generate comprehensive 
genomic-based signatures (a sort of map of alterations that have taken 
place) per individual cancer patient, and build up better information 
systems that enable collection and integration of multiple data 
(preferably of populations of diff erent ethnicities). Th is may lead 
to uncover unexplained disease risk and regulatory molecular 
events of cancer manifestation and progression, which might drive 
complicated courses of the disease [12]. Th is would in turn be 
another key turning point in the history of cancer research, and 
would improve our understanding of malignancy processes, tackle 
the increasing complexity (intra -/ inter - individual heterogeneity) 
of cancer patients, and clarify which genetic markers will be useful in 
clinical applications.
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